APA (7th ed.) Citation

Sho, T., Suda, G., Yamamoto, Y., Furuya, K., Baba, M., Ogawa, K., . . . Nakai, M. (2022). Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers, 14(16), 3938. https://doi.org/10.3390/cancers14163938

Chicago Style (17th ed.) Citation

Sho, Takuya, et al. "Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150." Cancers 14, no. 16 (2022): 3938. https://doi.org/10.3390/cancers14163938.

MLA (9th ed.) Citation

Sho, Takuya, et al. "Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150." Cancers, vol. 14, no. 16, 2022, p. 3938, https://doi.org/10.3390/cancers14163938.